EGFR-mutated, metastatic pulmonary pleomorphic carcinoma successfully treated with afatinib

Pulmonary pleomorphic carcinoma (PPC) has an aggressive clinical course and poor prognosis mainly because of the difficulty in achieving therapeutic effects. Despite a small fraction of patients with PPC possessing an epidermal growth factor receptor (EGFR) activating mutation, only a limited number...

Full description

Bibliographic Details
Main Authors: Akira Kawamura, Yuko Tanaka, Yusuke Inoue, Takashi Tsuchida, Mineo Katsumata, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Takafumi Suda
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000242

Similar Items